key: cord-0916078-p8on73cn authors: Crane, Kelly; Snead, Jessica; Stanley, Robert; Avery, Johnathan; Ghosh, Sumantra Monty; Mints, Gregory title: Case Reports or Case-Series: Intravenous buprenorphine micro-dosing induction in a patient on methadone treatment: a case report. date: 2020-07-25 journal: Psychosomatics DOI: 10.1016/j.psym.2020.07.004 sha: 4cc1ce8d928ab66f201dd307c86dd9173fb76a69 doc_id: 916078 cord_uid: p8on73cn INTRODUCTION: Buprenorphine in the treatment of opioid use disorder (OUD) has several benefits including better long-term treatment adherence (1) and is a safer option for many patients due to buprenorphine’s limited potential to cause respiratory depression (4). In comparison to standard buprenorphine induction, induction via micro-dosing does not require a period of withdrawal and dramatically shortens the time required to complete induction. Prior micro-dosing protocols using sublingual (SL) (7-10) and transdermal forms (11) have been reported. We present a case of buprenorphine induction using a novel inpatient intravenous micro-dosing 4-day protocol in a patient on methadone. CASE PRESENTATION: A 62-year-old man with chronic obstructive pulmonary disease (COPD) on chronic methadone 80mg daily for OUD presented with respiratory failure and was diagnosed with opioid overdose. He was transitioned from a naloxone infusion to intravenous micro-doses of buprenorphine and low dose methadone without experiencing significant withdrawal, and he was discharged on buprenorphine/naloxone SL. DISCUSSION: This case demonstrates a successful and well tolerated buprenorphine induction without interruption of methadone treatment or precipitation of significant opioid withdrawal. To the best of our knowledge, this is the first report describing micro-induction with intravenous buprenorphine. Methadone used in the treatment of opioid use disorder (OUD) can exacerbate respiratory insufficiency in patients with pulmonary and breathing disorders, such as chronic obstructive pulmonary disease (COPD) and obesity-hypoventilation syndrome (OHS). There are several options available to patients on methadone who are hospitalized for respiratory failure. The methadone dose can be decreased to avoid respiratory depression, patients can be detoxed off methadone completely, or, while still hospitalized, an alternative maintenance medication, such as long-acting injectable naltrexone or buprenorphine, can be initiated. Inpatient initiation of buprenorphine has been shown to result in better long-term treatment adherence and less illicit opioid use 6 months after hospitalization than detoxification 1 . Additionally, previous studies have demonstrated improved opioid relapse-free survival with buprenorphine maintenance than with long-acting injectable naltrexone 2 . Buprenorphine is a partial μ-opioid receptor agonist with high receptor binding affinity 3 and a limited potential to cause respiratory depression 4 . Initiation of buprenorphine is often fraught with concerns about precipitated withdrawal as well as the prolonged time period required for successful and safe transition. Standard buprenorphine induction requires patients to go through an initial period of moderate opioid withdrawal 5 . Opioid Withdrawal is unpleasant, unacceptable to many patients, and may decrease patient acceptance of the medication. Failure to wait long enough before buprenorphine induction typically leads to severe precipitated opioid withdrawal, which can be associated with agitation and delirium 6 . Increased duration of hospitalization is also frequently a concern due to cost and increased risk of patients leaving against medical advice, before the induction is completed. Thus, despite the impetus to starting maintenance treatment during hospitalization 1 , implementation of inpatient buprenorphine induction protocols remains challenging. Because of methadone's long half-life, the aforementioned challenges are particularly prominent with transition from methadone to buprenorphine. Unlike traditional induction, buprenorphine micro-dosing allows for initiation of buprenorphine without requiring a period of opioid withdrawal. Successful protocols utilizing sublingual (SL) 7-10 and transdermal 11 forms have been reported. Micro-dosing is intended to both improve tolerability and decrease duration of induction. Usual starting micro-doses of buprenorphine are 0.3-0.5 mg or 15-25% of the initial SL doses of the standard induction. Such low doses of buprenorphine are not available in SL formulation in the United States. The manufacture package insert instructs not to divide the tablets 12 and although the practice certainly exists 13 , local pharmacy policies vary among hospitals. The buprenorphine transdermal patch is available in small dosages, but it is not available in a generic form and is expensive 14 . In comparison, generic intravenous buprenorphine, which is usually used for pain management 15 , is readily available and is inexpensive 14 . We report a case of a patient successfully transitioned from methadone to buprenorphine during hospitalization using a novel intravenous buprenorphine micro-dosing protocol. The patient verbally consented to transition off methadone. Education about buprenorphine was provided. The patient expressed his strong preference to avoid withdrawal symptoms as much as possible. He was then offered a micro-dosing induction protocol with intravenous buprenorphine and was informed that this would be an off-label use of an otherwise FDAapproved medication. Potential side effects were reviewed, and the patient gave his verbal consent to proceed. Prior to discharge, the patient was asked for permission to submit this case report for publication, which he gave in writing. Intravenous buprenorphine was supplied in single use 1ml vials of 0.3 mg/ml buprenorphine. The dosing was based on reported bioavailability of the sublingual form of 30-50% 16, 17 . Q6h dosing schedule of intravenous buprenorphine dosing was chosen based on reported half-life of up to 8.6h (after a single dose of < 1mg) 18 and the standard recommendation of Q6-8h dosing for pain management. Buprenorphine was administered intravenously via a peripheral venous catheter as a rapid push. Though very rapid buprenorphine induction (8h) of a patient on 50mg of methadone daily has been reported 19 , we chose a conservative 4-day induction schedule similar to previously reported SL protocols 8 . The induction protocol and clinical course are summarized in table 1 Case A 62-year-old man on chronic methadone 80mg daily for OUD presented to his primary care provider feeling unwell. He was found to be lethargic, with an arterial oxygen saturation by pulse oximeter of 74% on room air, which improved to 96% with supplemental oxygen. He was referred to the emergency department (ED) of our hospital. On arrival to the ED, he was altered, had a respiratory rate of 6 per minute and pin-point pupils. Intravenous naloxone 0.4 mg was administered x 2 with improvement in his mental status and respiratory rate, confirming the diagnosis of opioid overdose. He was then (at 8pm on hospital day (HD) 1) started on continuous naloxone infusion at 0.06 mg/h. Methadone was held. Admission venous blood gas analysis is shown in table 2. Urine toxicology screen was positive for methadone and cannabis only. Blood ethanol level was undetectable. Liver and renal function were normal. He was admitted to the medicine service step down unit, where he remained until discharge. The patient had a history of obesity (on admission weight 101 kg, BMI 26.5 kg/m 2 ) and COPD. He used intranasal heroin intermittently for 20+ years. One year prior, the patient was admitted to the hospital with respiratory failure due to heroin overdose. He was since maintained on 80mg of methadone daily in his OTP. He could not specify when his last heroin use was but stated that it was not recent. He denied taking more methadone than prescribed. He reported one attempt at buprenorphine treatment 3 years prior and underwent induction at home. However, he stopped taking the medication soon thereafter when he relapsed on heroin. He lived alone in the New York City borough of the Bronx and was receiving disability benefits. The naloxone infusion was discontinued at 11am on HD 3. Methadone was restarted at 25mg Q12h at 5pm on HD 3. The intravenous buprenorphine micro-dosing induction protocol was initiated at 6pm on HD 3 (induction day 1) table 1. Except for a single short episode, the patient demonstrated very few, if any, signs or symptoms of opioid withdrawal (COWS 0-3) throughout his admission. On HD 4 (induction day 2), 2 hours after the administration of the 2 nd dose of 0.3mg buprenorphine, sweating, nausea, and yawning were reported. His COWS score was 10. Intravenous fluids, Ondansetron 8mg IV every 8 hours as needed, and Clonidine 0.1mg oral every 8 hours standing were administered with immediate resolution of his symptoms. He required a total of three doses of 8mg IV ondansetron between HD 4 and HD 5. The patient remained well until discharge (COWS 0-2). Clonidine was discontinued due to borderline low blood pressure on HD 6 (induction day 4). On HD 7 (induction day 5) the patient was transitioned to SL buprenorphine dosed every two hours until the total dose within the preceding 24h reached 16mg. This titration scheme was based on our previous experience, as well as others 20 . He was discharged on HD 8 with a prescription for buprenorphine/naloxone SL film 16mg/4mg daily and an appointment with his OTP, which also provided buprenorphine treatment. The patient was also prescribed 2L oxygen per NC on discharge and given an outpatient pulmonology referral with the working diagnosis of obesityhypoventilation syndrome. At 4 weeks post discharge, the patient had a telephone follow-up. He reported feeling well and denied any methadone or illicit opioid use since discharge, or any opioid cravings. Per patient, he was taking buprenorphine/naloxone as prescribed. However, he had been unable to connect to the outpatient buprenorphine provider, presumably because of the disruptions caused by the COVID-19 pandemic. At that time, his buprenorphine prescription was renewed, and additional steps were taken to ensure transition to an outpatient provider. We report a case of a patient with COPD, and likely OHS on methadone who was admitted with a second episode of acute respiratory failure. After initial treatment with continuous intravenous naloxone infusion, the patient underwent successful inpatient intravenous buprenorphine microdosing induction. The induction was performed without interruption of methadone treatment or precipitation of significant opioid withdrawal. To the best of our knowledge, this is the first report describing micro-induction with intravenous buprenorphine. An often-cited concern regarding intravenous administration of buprenorphine is a potential to cause euphoria or a "high". Indeed, intravenous buprenorphine caused euphoria in healthy adults not on opioids 21 and in patients with OUD who completed inpatient detox 22 . SL buprenorphine is routinely diverted to be crushed and injected intravenously 23 because it can cause a high. It should be noted, however, that because SL bioavailability of buprenorphine is 30-50% 16, 17 , such injection would result in drug blood levels 2-3 times higher than intended. Additionally, SL doses of the drug used for OUD maintenance are 2 orders of magnitude higher than those used for pain control 15 . We are unaware of any reports suggesting that analgesic (0.1-1mg) doses of intravenous buprenorphine would cause euphoria in patients already on high doses of opioids, including methadone. We therefore considered this approach safe. Notably, our patient specifically reported (and was surprised by) lack of any euphoric effect of the medication. During the induction the patient had a single episode of mild opioid withdrawal, which was brief and easily managed. The symptoms occurred only once the 24-hour cumulative dose of buprenorphine reached 0.9 mg (approximately 9 mcg/kg). This is consistent with a previous report that in methadone overdose, 10 mcg/kg of intravenous buprenorphine caused no withdrawal, and 15 mcg/kg resulted in, at most, mild withdrawal symptoms 24 The withdrawal occurred 2 hours after a dose of intravenous buprenorphine, much later than the expected brain tissue peak concentration 25 . We therefore speculate that the withdrawal was related to the CNS level of methadone, rather than of buprenorphine. Methadone was administered Q12h and the withdrawal episode occurred at the tail end of its dosing interval at approximately 10 hours. We wonder whether the withdrawal could have been avoided if we chose a Q8h dosing schedule of methadone. Our micro-induction protocol was completed over just 4 days. In comparison, standard induction for an inpatient on 80 mg of methadone would take at least 2 weeks to complete. We report a case of successful and well tolerated buprenorphine induction using a novel inpatient intravenous micro-dosing 4-day protocol in a patient on methadone. We believe this to be a promising approach and further investigation into even shorter protocols utilizing intravenous buprenorphine is warranted. Buprenorphine treatment for hospitalized, opioid-dependent patients: A randomized clinical trial Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations Buprenorphine induces ceiling in respiratory depression but not in analgesia Statement of the American society of addiction Rehabil Switching From High-Dose, Long-Term Opioids to Buprenorphine: A Case Series Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol The clinical analgesic efficacy of buprenorphine Bioavailability of Sublingual Buprenorphine Human Pharmacokinetics of Intravenous, Sublingual, and Buccal Buprenorphine Evaluation of the Pharmacokinetics of Single-and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers A Review of Novel Methods to Support the Transition from Methadone and Other Full Agonist Opioids to Sublingual in Both Community and Acute Care Settings Remote Buprenorphine-Naloxone Initiation as an Essential Service for People with Chronic Pain and Opioid Dependence During the COVID-19 Pandemic: Case Reports, Clinical Pathways, and Implications for the Future Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Buprenorphine and Morphine in Normal Volunteers Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals Buprenorphine in the United States: Motives for abuse, misuse, and diversion Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: A prospective randomized trial A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration